Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278925 · ClinicalTrials.gov registry record · Phase 1
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis
A Phase 1 study of Cirrhosis, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT03278925 is a Phase 1 study of Cirrhosis that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03278925, a Phase 1 study of Cirrhosis, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of defined green tea catechin extract and to see how well it works in preventing liver cancer in participants with cirrhosis. Higher levels of the molecule gamma-OHPdG may be found in participants with cirrhosis, which may mean a higher risk of the development of liver cancer. Defined green tea catechin extract may work better to lower levels of gamma-OHPdG and prevent the development of liver cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- OTHER Laboratory Biomarker Analysis
- DRUG Defined Green Tea Catechin Extract
Study Locations (2)
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Other
- University of Puerto Rico - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03278925
The ClinicalTrials.gov registry entry for NCT03278925 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cirrhosis appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03278925 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Other.
Frequently Asked Questions
What is clinical trial NCT03278925 about?
NCT03278925 is a clinical study titled "Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis". This phase I trial studies the side effects and best dose of defined green tea catechin extract and to see how well it works in preventing liver cancer in participants with cirrhosis. Higher levels of the molecule gamma-OHPdG may be found in participants with cirrhosis, which may mean a higher risk ...
What is the current status of trial NCT03278925?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-08-09. Estimated completion is 2024-12-31.
What conditions does trial NCT03278925 study?
This clinical trial studies the following conditions: Cirrhosis.
What interventions are being tested in trial NCT03278925?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Defined Green Tea Catechin Extract (DRUG).
Who is sponsoring clinical trial NCT03278925?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03278925 being conducted?
This trial has 2 study locations across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
RECRUITING · Phase 1
-
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
RECRUITING · Phase 1
-
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 1
-
FMT in Cirrhosis and Hepatic Encephalopathy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.